There is a well-known analogy, called a “String of Pearls,” that has gained recognition within the biotech/pharma industry. It was initially introduced by a respected leader in the industry to signify a strategic management concept of focusing upon an enterprise’s clearly defined areas of therapeutic strength and then strategically deciding upon which acquisition opportunities to pursue within those confines. We use the term differently. When describing our TILAC™ platform we envision a coherent “string” of disease states upon which this approach can be focused. The outcomes in each disease constitute “polished pearls” in our analogy. Each mechanism for creating the pearls is strikingly similar, even though the diseases being treated appear to be very different, manifesting different symptoms within the broad scope of inflammatory and autoimmune diseases.
TTregTherapeutics’ TILAC platform is truly transformative in its simplicity, its elegance, and its universal application. The platform is centered on an underlying mechanism of action that is a common denominator among all inflammatory diseases. The premise is that, built upon this platform, unique tolerogenic treatments for specific diseases can be advanced that can ultimately eliminate the pathological immune response associated with each of them. Healing and restoration are the goals. TregTherapeutics is, thus, a purveyor of pearls, each presenting a elegant solution for a particular disease, strung upon the commonality of the mechanism of the TILAC platform – a thing of beauty and a foundation for the dream that will free people from the scourge of chronic inflammatory disease. A string of pearls that will change the world – transformative, paradigm-shifting, holding forth the promise of change for millions of patients suffering with these devastating diseases. A simple therapeutic concept – one centered on the principle that the immune system can heal itself with one powerful nudge from the TILAC™ approach – orchestrating healing from disease – truly a worthwhile enterprise.